TCR-based Therapies for Solid Tumors Summit

Memo

The first TCR-based therapy approval in the US and Europe at the start of this year sparked a rush of excitement, investment and collaborations. As further developers move into the clinic and some near commercialization, it's time for this community to unite to address the critical bottlenecks faced in development, from discovery to approval, to guarantee smooth sailing through the clinic.The 4th TCR-based Therapies for Solid Tumors Summit is returning to Boston as the must-attend forum for TCR experts to come together to share industry updates and next generation engineered approaches to boost therapy safety and efficacy.Join leaders and newcomers including Immunocore, Medigene, Immatics, Captain T Cell and Anocca as they collaborate to guarantee tumor-specificity, prevent cross-reactivity, boost TCR and target discovery, enhance solid tumor durability and explore TCR modalities.Huge milestones were achieved for the TCR field in 2022, however, there's no time to sit back and relax. Collaborate with like-minded TCR trailblazers to secure clinical validation and streamline the road from discovery to commercialization.URLs:Tickets: https://go.evvnt.com/1444012-2?pid=5569 Brochure: https://go.evvnt.com/1444012-3?pid=5569 Date and Time: On Monday April 03, 2023 at 9:00 am to Wednesday April 05, 2023 at 4:30 pmVenue details: Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, Massachusetts, 02111, United States   Prices:Drug Developer - Conference + 2 Workshops: USD 4197.00,Drug Developer - Conference + 1 Workshop: USD 3548.00,Drug Developer - Conference Only: USD 2999.00,Academic and Start Up - Conference + 2 Workshops: USD 3597.00,Academic and Start Up - Conference + 1 Workshop: USD 3048.00,Academic and Start Up - Conference Only: USD 2599.00,Standard - Conference + 2 Workshops: USD 5997.00,Standard - Conference + 1 Workshop: USD 4298.00,Standard - Conference Only: USD 3599.00Speakers: Birgit Schultes, Senior Vice President, Cell Therapy, Intellia Therapeutics, Claudia Wagner, Senior Director, Immunology, Head of TCR Discovery and Validation, Immatics, David Scheinberg, Director, Experimental Therapeutics Center, Memorial Sloan Kettering Cancer Center, Dolores Schendel, Chief Scientific Officer, Medigene AG, Estelle Marrer-Berger, Chief Development Officer, 3T Biosciences, Felix Lorenz, Chief Executive and Scientific Officer, Captain T Cell, Gang Zeng, President and Chief Executive Officer, T-Cure Bioscience, Joseph Dukes, Head of Research, Enara Bio, Kumar Karyampudi, Technical Director, Cell Therapy Facility, Moffitt Cancer Center, Leonardo Borras, Chief Scientific Officer, CDR-Life, Mark Throsby, Chief Scientific Officer, Gadeta, Paul Lammers, Chief Executive Officer, Triumvira Immunologics, Peggy Sotiropoulou, Chief Scientific Officer, T-knife Therapeutics, Ralph Torbay, Chief Commercial Officer, Immunocore, Reagan Jarvis, Chief Executive Officer, Anocca, Robert Salzler, Scientist, Proteomics and Immunopeptidomics, Regeneron Pharmaceuticals, Robert Tighe, Vice President - Research, TCR2 Therapeutics, Shawn Kubli, Head Cell Therapy Division, Treadwell Therapeutics, Shawn Kubli, Head, Cell Therapy Division, Treadwell Therapeutics, Thomas Andresen, Chief Executive Officer, T-Cypher Bio, Zhen Su, Chief Executive Officer and Director, Marengo Therapeutics Inc.